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Ischemic stroke patients are at high risk of having new cardio-vascular events. The cumulative risk of vascular recurrence after 
a first stroke reaches up to 48% at 10 years.1 Acetylsalicylic acid 
(aspirin) and clopidogrel are the most widely used antiplatelet 
agents in secondary prevention of stroke. Aspirin has been associ-
ated with a relative risk reduction of 25% in secondary cardiovas-
cular events and 13% to 15% in secondary prevention of stroke.2 
A high platelet reactivity phenotype can be present in ≤60% of 
aspirin-treated patients and has been associated with an increased 
risk of recurrent ischemic events, and although it is a substantially 
heritable phenotype, very few genetic determinant have been 
identified. Furthermore, the causes of aspirin failure goes beyond 
high platelet reactivity and are still largely unknown.3
Only polymorphisms in PEAR1 have been confirmed 
as genetic risk factors of aspirin failure.4 The rs12041331 
polymorphism is associated with platelet aggregation, 
increased platelet reactivity,5 and vascular recurrence in 
aspirin-treated patients,4 although these polymorphisms do 
not explain the whole variability observed in aspirin resis-
tance or in vascular responsiveness. Other genomic regula-
tions, such as epigenetics modifications could be associated 
with the risk of vascular recurrence in patients treated with 
aspirin.
We aimed to analyze the whole epigenome of stroke 
patients treated with aspirin, to find altered methylation sites 
associated with vascular recurrence.
Background and Purpose—Despite great efforts by pharmacogenetic studies, the causes of aspirin failure to prevent the 
recurrence of ischemic events remain unclear. Our aim was to study whether epigenetics could be associated with the risk 
of vascular recurrence in aspirin-treated stroke patients.
Methods—We performed an epigenetic joint analysis study in 327 patients treated with aspirin. In the discovery stage, we 
performed a nested case–control study in 38 matched ischemic stroke patients in whom 450 000 methylation sites were 
analyzed. Nineteen patients presented vascular recurrence after stroke, and 19 matched patients did not present vascular 
recurrence during the first year of follow-up. In a second stage, 289 new patients were analyzed by EpiTYPER.
Results—The following 3 differentially methylated candidate CpG sites, were identified in the discovery stage and analyzed 
in the second stage: cg26039762 (P=9.69×10−06, RAF1), cg04985020 (P=3.47×10−03, PPM1A), and cg08419850 
(P=3.47×10−03, KCNQ1). Joint analysis identified an epigenome-wide association for cg04985020 (PPM1A; P=1.78×10−07), 
with vascular recurrence in patients treated with aspirin.
Conclusions—The pattern of differential methylation in PPM1A is associated with vascular recurrence in aspirin-treated 
stroke patients.   (Stroke. 2016;47:1926-1929. DOI: 10.1161/STROKEAHA.116.013340.)
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Materials and Methods
Study Patients
Thirty-eight subjects from a cohort of 1900 ischemic stroke patients 
recruited prospectively at Vall d’Hebron Hospital (Spain), who 
started aspirin treatment after a first ischemic stroke, were ana-
lyzed. Nineteen participants presented a new vascular event (isch-
emic stroke, myocardial infarction, peripheral vascular disease, or 
cardiovascular death) during the first year of follow-up and were 
matched one-to-one (age, sex, TOAST [Trial of Org 10172 in Acute 
Stroke Treatment]) with 19 participants without a vascular event. 
Second-stage analysis was performed in 289 prospective enrolled 
participants from 4 independent cohorts with ischemic stroke or 
ischemic atherothrombotic disease; 29 presented a vascular recur-
rence within 1 year of follow-up (Table I in the online-only Data 
Supplement).
Discovery: HumanMethylation450 Assay
DNA was extracted from blood samples using standard methods. 
Samples were obtained during the first 24 hours after stroke onset, 
before initial aspirin administration.
Genome-wide DNA methylation (DNAm) was assessed using 
the HumanMethylation450 (Illumina) assay. All samples (n=38) 
were processed in a single working batch. Quality Control and dif-
ferentially methylated CpG (DMC) sites analysis were performed as 
described elsewhere,6 using the R computing environment (3.1.3 ver-
sion; Table II in the online-only Data Supplement).
Rs120411331 polymorphism (PEAR1) was checked to discover 
whether it could be a confounding factor in the EWAS (Epigenome-
Wide Association Study) analysis.
CpGs Selection
One DMC with epigenome-wide significance7 (RAF1; P<10−06) was 
selected for further replication. Candidate DMCs for second-stage 
analysis were defined as: top 100 significant DMCs from the uni-
variate analysis, which also appear in the top 100 DMCs after multi-
variable analysis. Multivariable analyses were adjusted for principal 
components and DNAm potential covariates (age, sex, and current 
smoking). From a total of 36 candidate CpGs, those mapped on genes 
previously associated with cardiovascular disease were considered 
for further analysis. A PubMed search (http://www.ncbi.nlm.nih.
gov/pubmed) was undertaken using the following key words: aspirin, 
atherosclerosis, cardiovascular, stroke, and vascular. Finally, from 4 
candidate DMCs, only 2 CpGs (PPM1A and KCNQ1) were located in 
regions suitable for EpiTYPER analysis (Figure IV in the online-only 
Data Supplement).
Figure. A, Manhattan plot for the EWAS (Epigenome-Wide Association Study) of aspirin-treated stroke patients. x axis: chromosome 
position; y axis: −log10 of P values. B, Hierarchical cluster analysis of most significant differentially methylated CpG associated (Table) with 
vascular recurrence. CA indicates recurrence patients; and CO, nonrecurrence patients.
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Second-Stage EpiTYPER Assay
An averaged 400-bp region was sequenced using EpiTYPER 
(Sequenom) around each CpG selected from the discovery stage in 
289 new patients.
Statistical Analysis
DMC sites were calculated using the Mann–Whitney U test and 
multivariable generalized linear analysis. Sample size calculation 
indicated that 19 subjects per condition were needed to achieve a 
10−05 significance level and 80% statistical power. A joint analysis 
strategy using the DerSimonian–Laid test was performed to increase 
the statistical power in the 2-stage study as previously suggested.8
Complete methodology is available in the Materials and Methods 
section in the online-only Data Supplement.
Results
Discovery
DNAm levels were obtained for 485 577 CpGs sites (Figure [A]). 
After data preprocessing and quality control analysis one DMC 
was associated with vascular recurrence at epigenomewide level 
(P<10−06), covariant adjustment analysis was also performed 
(Table; Table IV in the online-only Data Supplement). Table 
IV in the online-only Data Supplement shows the 36 candidate 
CpG sites which were best ranked in both univariate and covari-
ate analyses, including cg04985020 (PPM1A) and cg08419850 
(KCNQ1). Figure (B) shows a hierarchical cluster analysis, 
which was able to distinguish vascular recurrence patients from 
nonvascular patients, with only 2 samples misclassified.
Second-Stage Analysis
Second-stage analysis was performed for the epigenome-
wide significant CpG, cg26039762 (RAF1; P=9.69×10−06), 
and 2 additional candidate CpG sites, cg04985020 (PPM1A; 
P=3.46×10−04) and cg08419850 (KCNQ1; P=3.46×10−04). All 
3 CpGs map genes involved in atherosclerosis and vascular 
process. The cg04985020 (PPM1A) was associated with vas-
cular recurrence (P=0.027). The same cg04985020 methyla-
tion pattern was observed in each of the 4 validation-stage 
cohorts and when nonstroke and cardioembolic patients were 
excluded from the analyses (Materials and Methods section 
in the online-only Data Supplement). Additionally, the fol-
lowing 3 CpG sites surrounding cg26039762 (RAF1) were 
de novo associated with vascular recurrence: RAR1_10 
(P=0.0015), RAF1_6 (P=0.0043), and RAF1_3 (P=0.01; 
Table VI in the online-only Data Supplement). However, 
cg26039762 (RAF1) and cg08419850 (KCNQ1) were not 
associated in this second stage.
Joint analysis of discovery and replication stage revealed 
an epigenome-wide statistically significant meta P value8 for 
PPM1A (meta P=1.78×10−07) but not for RAF1. PPM1A was 
independently associated with vascular recurrence when ana-
lyzed possible DNAm confounding factors (age, sex, and cur-
rent smoking; P=5.74×10−03) and also PEAR1 polymorphism 
(rs12041331; P=9.82×10−03). Additionally, PPM1A methyla-
tion levels were not influenced by cell-type proportions.
Discussion
Patients with vascular recurrence presented higher meth-
ylation levels of cg04985020 CpG (PPM1A) compared with 
nonrecurrent patients. Despite cg04985020 not being sig-
nificant on the epigenome-wide level, in the discovery stage 
(P=3.46×10−04), the joint analysis revealed a meta P value of 
1.78×10−07 that was significant on the epigenome-wide level.7 
These results suggest an association between DNAm levels of 
PPM1A and vascular recurrence during on-aspirin treatment, 
regardless of the disease (cardiovascular or stroke). The asso-
ciation was not confounded by common DNAm confounding 
factors or PEAR1 polymorphism. The cg26039762 (RAF1) 
was not replicated, but 3 surrounding CpGs were associ-
ated de novo with vascular recurrence. Patients with vascu-
lar recurrence presented lower methylation levels of these 3 
surrounding CpGs compared with nonvascular recurrence 
patients, similar to cg26039762 (RAF1) in the discovery stage. 
Additionally, hierarchical cluster analysis showed a potential 
role of DMCs as a model to classify patients within highest or 
lowest risk of vascular recurrence.
Protein phosphatase magnesium dependent 1A (PPM1A) 
is involved in the regulation of transforming growth factor 
(TGF)-β1 signaling and plasminogen activator inhibitor-1 
transcription.9 Plasminogen activator inhibitor-1 levels are 
associated with increased risk of cardiovascular events, par-
ticularly in the context of elevated tissue TGF-β1.10 Raf1 proto-
oncogene, serine/threonine kinase (RAF1), has been described 
in many vascular diseases, such as vascular dementia, angio-
genesis processes, or cardiovascular events.11 RAF1 has also 
been described as taking part in signal transduction in the 
TGF-β/Smad pathway.12 Furthermore, aspirin administration 
has been associated with decreasing TGF-β1 serum levels in 
hypercholesterolemic rats.13 We hypothesize that PPM1A- and 
RAF1-altered methylation could be associated with vascular 
Table.  DMC Sites Associated With Vascular Recurrence 
(P<10−05)
DMCs Associated With Vascular Recurrence. Univariate Analysis.
CpG ID Gene P Value
cg26039762 RAF1 9.69×10−6
cg00094487 SPG21 1.20×10−5














DMC indicates differentially methylated CpG.
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recurrence because of the regulation of the TGF-β pathway; 
however, further studies are needed to confirm this hypothesis.
Pharmacoepigenomics is a growing field that could be used 
in the future to assist in personalized antiplatelet therapy or to 
find potential new drug targets. Our study suggests a remark-
able role for epigenetics in the modulation of aspirin response.
Limitations
The small sample size in the discovery stage impeded the 
achievement of more significant values; however, joint anal-
ysis was useful to improve the results of our study. mRNA 
studies are needed to confirm the biological significance of 
our results.
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